In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Next Up For Cubist: A Future That Includes Optimer, Trius

Executive Summary

Cubist Pharmaceuticals will strengthen its position in the challenging antibiotic market with the acquisitions of two rivals, Optimer Pharmaceuticals and Trius Therapeutics. But it was Cubist’s current strength that allowed it to get those deals done on favorable, risk-sharing terms.

Advertisement

Related Content

Biopharma Dealmaking Quarterly Statistics, Q3 2013
Merck’s “Beyond The Pill” Bet, Vree Health, Goes Commercial
Financings Of The Fortnight: Is Google/Calico The Start Of A Wave Of Funding Alternatives?
CDC’s Antibiotic-Resistance Battle Plan Emphasizes Preserving Current Drugs
Two New Sides Of Cubist: Antibiotics Maker Buys Both Optimer And Trius
Trius Antibiotic Tedizolid Hits Old, New And In-Between Endpoints
Optimer Is Up For Sale And Could Attract Hospital-Focused Suitors
Optimer's Early Sales Of Dificid Topping Analyst Projections
Cubist Gets Entereg And A Late-Stage Compound With Adolor Buy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004092

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel